Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The third time may be the charm for Framingham, Mass.-based Alzheon when it comes to an initial public offering – because the company has balked the first two times it attempted to go public on the stock exchange.
In 2018 alone, mergers and acquisitions (M&A) activity among the life sciences industry totaled US$198B according to the 2019 EY M&A Firepower Report. The report continues on to state that “Life sciences M&A in 2018 was strong but failed to meet market expectations as companies focused on portfolio optimization.”
Despite the government shutdown, at least two biotech companies, Kaleido Biosciences and Cirius Therapeutics, have filed with the U.S. Securities and Exchange Commission (SEC) for initial public offerings (IPO).
With the JP Morgan Healthcare Conference ending today, it’s worth noting the word “healthcare” in the title, not “biopharma.” It’s not as if the biotech and pharmaceutical industry isn’t part of healthcare, but BioSpace’s reporting focuses on biopharma. Here’s a look at some of the more healthcare-oriented stories coming out of San Francisco this week.
On Tuesday, Takeda Pharmaceutical finally wrapped up its $62 billion acquisition of Shire plc. As the combined companies continue to merge and shape their combined roles, Chief Executive Officer Christophe Weber is already eying potential deals to offset some of the debt the company garnered.
Galapagos NV received a transparency notification from Sands Capital Management, LLC.
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
Yesterday, shareholders filed for a class action lawsuit against Tesaro in Delaware federal court, alleging that the merger is based on misleading financial analyses filed with the U.S. Securities and Exchange Commission (SEC).
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.